Share chart Immunocore Holdings plc
Extended chart
Simple chart
About Immunocore Holdings plc
Immunocore Holdings Limited, биотехнологическая компания поздней стадии, разрабатывает иммунотерапию для лечения онкологических, инфекционных и аутоиммунных заболеваний. Ведущим онкологическим терапевтическим кандидатом компании является тебентафусп, который проходит рандомизированное клиническое исследование III фазы у пациентов с ранее нелеченой метастатической увеальной меланомой, раком, который, как исторически доказано, нечувствителен к другим иммунотерапевтическим средствам. more details| IPO date | 2021-02-05 |
|---|---|
| ISIN | US45258D1054 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | https://www.immunocore.com |
| Цена ао | 28.27 |
| Change price per day: | 0% (28.27) |
|---|---|
| Change price per week: | -5.13% (29.8) |
| Change price per month: | -4.36% (29.56) |
| Change price per 3 month: | -2.21% (28.91) |
| Change price per half year: | -14.33% (33) |
| Change price per year: | -53.53% (60.83) |
| Change price per 3 year: | -20.34% (35.49) |
| Change price per 5 year: | 0% (28.27) |
| Change price per 10 year: | 0% (28.27) |
| Change price per year to date: | -1.36% (28.66) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Transaction date | Date of disclosure | Insider | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
|---|---|---|---|---|---|---|---|---|---|
| 17.03.2025 | 17.03.2025 | Brian Di Donato affiliate |
Purchase | 30 | 3 000 000 | 100000 | 0 | 0.23 | link |
| Institutions | Volume | Share, % |
|---|---|---|
| RTW Investments LP | 6096387 | 12.24 |
| Wellington Management Group, LLP | 4312611 | 8.66 |
| Price (T.Rowe) Associates Inc | 2944574 | 5.91 |
| Rock Springs Capital Management, LP | 2661507 | 5.34 |
| Baker Brothers Advisors, LLC | 2520731 | 5.06 |
| FMR, LLC | 1696386 | 3.41 |
| Paradigm Biocapital Advisors LP | 1453883 | 2.92 |
| Bellevue Group AG | 976054 | 1.96 |
| General Atlantic, L.P. | 950000 | 1.91 |
| Morgan Stanley | 917063 | 1.84 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| Virtus LifeSci Biotech Products ETF | 1.24883 | 36.79 | 0.13953 |
| Range Cancer Therapeutics ETF | 0.78301 | 47.24 | 0.11955 |
| Future Tech ETF | 0.12499 | 426.34 | 0.8416 |
| Principal Healthcare Innovators ETF | 0.12499 | 618.5 | 0.8416 |
| Invesco Nasdaq Biotechnology ETF | 0.12304 | 28.58 | 0.8565 |
| ProShares Ultra Nasdaq Biotechnology | 0.08533 | 51.7 | 0.85651 |
| Goldman Sachs Innovate Equity ETF | 0.06941 | 29.66 | 1.20987 |
SPDR Portfolio Developed World ex-US ETF
|
0.0075 | 5.29 | 3.28401 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Bahija Jallal Ph.D. | CEO & Executive Director | 1.42M | 1961 (64 years) |
| Ms. Annelise Vuidepot Ph.D. | Senior VP, CTO and Research & UK Site Lead | N/A | |
| Clayton Robertson | Head of Investor Relations | N/A | |
| Mr. Brian R. Di Donato M.B.A. | Executive VP, CFO & Strategy | N/A | 1967 (58 years) |
| Ms. Lily Margaret Hepworth | Senior VP, General Counsel & Company Secretary | N/A | 1983 (42 years) |
| Mr. John Trainer M.B.A. | SVP & Chief Operating Officer | N/A | 1974 (51 year) |
| Mr. John Goll III | SVP, Finance & Chief Accounting Officer | N/A | |
| Mr. Sean D. Buckley | VP & Chief Information Officer | N/A | 1983 (42 years) |
| Ms. Tina St. Leger | Chief Human Resources Officer | 1968 (57 years) | |
| Dr. David Berman M.D., Ph.D. | Executive Vice President of Research & Development | 1971 (54 years) |
Address: United Kingdom, Abingdon OX RY, 92 Park Drive - open in Google maps, open in Yandex maps
Website: https://www.immunocore.com
Website: https://www.immunocore.com
